Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine

European Journal of Immunology

Volumn 43, Issue 7, 2013, Pages 1940-1952

  Mullarkey, Caitlin E ^a   Boyd, Amy ^a   Van Laarhoven, Arjan ^a   Lefevre, Eric A ^b   Veronica Carr, B ^b   Baratelli, Massimiliano ^c   Molesti, Eleonora ^d   Temperton, Nigel J ^d   Butter, Colin ^b   Charleston, Bryan ^b   Lambe, Teresa ^a   Gilbert, Sarah C ^a  

^a UK   (United Kingdom)

^b INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^c CENTRE DE RECERCA EN SANITAT ANIMAL CRESA   (Spain)

^d MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

Author keywords

Adjuvants; Influenza vaccines; T cells; Vaccination

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MATRIX PROTEIN; VIRUS ANTIBODY; VIRUS NUCLEOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEASONAL INFLUENZA; T LYMPHOCYTE ACTIVATION; VIRUS NEUTRALIZATION;

ADJUVANTS; INFLUENZA VACCINES; T CELLS; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BIRDS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS; INFLUENZA VACCINES; MALE; MICE; MICE, INBRED C57BL; NUCLEOPROTEINS; SUS SCROFA; SWINE; VIRAL CORE PROTEINS; VIRAL VACCINES;

EID: 84880022591     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242922     Document Type: Article

References (34)

1. Grebe, K. M., Yewdell, J. W. and Bennink, J. R., Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect. 2008. 10: 1024-1029.
2. Ellebedy, A. H. and Webby, R. J., Influenza vaccines. Vaccine 2009. 27: D65-D68.
3. Petrie, J. G., Ohmit, S. E., Johnson, E., Cross, R. T. and Monto, A. S., Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J. Infect. Dis. 2011. 203: 1309-1315.
4. Osterholm, M. T., Kelley, N. S., Sommer, A. and Belongia, E. A., Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 2012. 12: 36-44.
5. Wei, C. J., Boyington, J. C., McTamney, P. M., Kong, W. P., Pearce, M. B., Xu, L., Andersen, H. et al., Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010. 329: 1060-1064.
6. McMichael, A. J., Gotch, F. M., Noble, G. R. and Beare, P. A. S., Cyto-toxic T-cell immunity to influenza. N. Engl. J. Med. 1983. 309: 13-17.
7. Wilkinson, T. M., Li, C. K. F., Chui, C. S. C., Huang, A. K. Y., Perkins, M., Liebner, J. C., Lambkin-Williams, R. et al., Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 2012. 18: 274-280.
8. McMichael, A. J., Dongworth, D. W., Gotch, F. M., Clark, A. and Potter, C. W., Declining T-cell immunity to influenza, 1977-82. Lancet 1983. 322: 762-764.
9. Berthoud, T. K., Hamill, M., Lillie, P. J., Hwenda, L., Collins, K. A., Ewer, K. J., Milicic, A. et al., Potent CD8 +T-cell immunogenicity in humans of a novel heterosubtypic influenza a vaccine, MVA-NP+M1. Clin. Infect. Dis. 2011. 52: 1-7.
10. Lillie, P. J., Berthoud, T. K., Powell, T. J., Lambe, T., Mullarkey, C., Spencer, A. J., Hamill, M. et al., Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin. Infect. Dis. 2012. 55: 19-25.
11. Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Hua, T., Nakaya, H. I., Ravindran, R. et al., Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011. 470: 543-U136.
12. Powell, T. J., Fox, A., Peng, Y., Le Thi Quynh, M., Lien, V. T. K., Hang, N. L. K., Wang, L. et al., Identification of H5N1-specific T-cell responses in a high-risk cohort in Vietnam indicates the existence of potential asymptomatic infections. J. Infect. Dis. 2012. 205: 20-27.
13. Nolan, T. M., Richmond, P. C., Skeljo, M. V., Pearce, G., Hartel, G., Formica, N. T., Höschler, K. et al., Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 2008. 26: 4160-4167.
14. Stephenson, I., Bugarini, R., Nicholson, K. G., Podda, A., Wood, J. M., Zambon, M. C. and Katz, J. M., Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 2005. 191: 1210-1215.
15. Leroux-Roels, I., Borkowski, A., Vanwolleghem, T., Dramé, M., Clement, F., Hons, E., Devaster, J.-M. et al., Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 370: 580-589.
16. Nakayama, T., Kashiwagi, Y., Kawashima, H., Kumagai, T., Ishii, K. J. and Ihara, T., Alum-adjuvanted H5N1 whole virion inactivated vaccine (WIV) enhanced inflammatory cytokine productions. Vaccine 2012. 30: 3885-3890.
17. Kreijtz, J. H. C. M., Suezer, Y., de Mutsert, G., van Amerongen, G., Schwantes, A., van den Brand, J. M. A., Fouchier, R. A. M. et al., MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PLoS ONE 2009. 4: e7790.
18. Toro, H., van Ginkel, F. W., Tang, D. C. C., Schemera, B., Rodning, S. and Newton, J., Avian influenza vaccination in chickens and pigs with replication-competent adenovirus free human recombinant adenovirus 5. Avian Dis. 2010. 54: 224-231.
19. Toro, H., Suarez, D. L., Tang, D. C. C., van Ginkel, F. W. and Breedlove, C., Avian influenza mucosal vaccination in chickens with replication-defective recombinant adenovirus vaccine. Avian Dis. 2011. 55: 43-47.
20. Brown, I. H., The epidemiology and evolution of influenza viruses in pigs. Vet. Microbiol. 2000. 74: 29-46.
21. Hutchings, C. L., Gilbert, S. C., Hill, A. V. S. and Moore, A. C., Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J. Immunol. 2005. 175: 599-606.
22. Russell, S. M. and Liew, F. Y., T cells primed by influenza virion internal components can cooperate in the antibody response to haemagglutinin. Nature 1979. 280: 147-148.
23. Russell, S. M. and Liew, F. Y., Cell cooperation in antibody responses to influenza virus. I. Priming of helper T cells by internal components of the virion. Eur. J. Immunol. 1980. 10: 791-796.
24. Schmitz, N., Beerli, R. R., Bauer, M., Jegerlehner, A., Dietmeier, K., Maudrich, M., Pumpens, P. et al., Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur. J. Immunol. 2012. 42: 863-869.
25. Veits, J., Römer-Oberdörfer, A., Helferich, D., Durban, M., Suezer, Y., Sutter, G. and Mettenleiter, T. C., Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine 2008. 26: 1688-1696.
26. Boyd, A. C., Ruiz-Hernandez, R., Peroval, M. Y., Carson, C., Balkissoon, D., Staines, K., Turner, A. V. et al., Towards a universal vaccine for avian influenza: protective efficacy of modified vaccinia virus Ankara and adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus. Vaccine 2013. 31: 670-675.
27. Lefevre, E. A., Carr, B. V., Inman, C. F., Prentice, H., Brown, I. H., Brookes, S. M., Garcon, F. et al., Immune responses in pigs vaccinated with adjuvanted and non-adjuvanted A(H1N1)pdm/09 influenza vaccines used in human immunization programmes. Plos ONE 2012. 7: e32400.
28. Antrobus, R. D., Lillie, P. J., Berthoud, T. K., Spencer, A. J., McLaren, J. E., Ladell, K., Lambe, T. et al., A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS ONE 2012. 7: e48322.
29. Draper, S. J., Moore, A. C., Goodman, A. L., Long, C. A., Holder, A. A., Gilbert, S. C., Hill, F. et al., Effective induction of high-titer antibodies by viral vector vaccines. Nat. Med. 2008. 14: 819-821.
30. Dicks, M. D. J., Spencer, A. J., Edwards, N. J., Wadell, G., Bojang, K., Gilbert, S. C., Hill, A. V. S. et al., A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE 2012. 7: e40385.
31. Miura, K., Orcutt, A. C., Muratova, O. V., Miller, L. H., Saul, A. and Long, C. A., Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 2008. 26: 193-200.
32. Temperton, N. J., Hoschler, K., Major, D., Nicolson, C., Manvell, R., Hien, V. M., Ha, D. Q. et al., A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respi. Viruses 2007. 1: 105-112.
33. Webster R. G., Cox N. J. and Sthor K., WHO manual on animal influenza diagnosis and surveillance. World Health Organization, Geneva, Switzerland. 2002
34. de Cassan, S. C., Forbes, E. K., Douglas, A. D., Milicic, A., Singh, B., Gupta, P., Chauhan, V. S. et al., The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J. Immunol. 2011. 187: 2602-2616.